Buparlisib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Buparlisib
Accession Number
DB11666
Description

Buparlisib has been used in trials studying the treatment and basic science of Lymphoma, Metastases, Lung Cancer, Solid Tumors, and Breast Cancer, among others.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 410.3935
Monoisotopic: 410.167808561
Chemical Formula
C18H21F3N6O2
Synonyms
  • Buparlisib
  • Buparlisibum
External IDs
  • BKM 120
  • BKM-120
  • BKM-120NX
  • NVP-BKM-120
  • NVP-BKM120

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Product Ingredients
IngredientUNIICASInChI Key
Buparlisib hydrochloride194LK4P5K11312445-63-8DGPLYAXBXJXEID-UHFFFAOYSA-N

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as pyridinylpyrimidines. These are compounds containing a pyridinylpyrimidine skeleton, which consists of a pyridine linked (not fused) to a pyrimidine by a bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Pyridinylpyrimidines
Alternative Parents
Dialkylarylamines / Aminopyrimidines and derivatives / Aminopyridines and derivatives / Morpholines / Imidolactams / Heteroaromatic compounds / Oxacyclic compounds / Dialkyl ethers / Azacyclic compounds / Primary amines
show 4 more
Substituents
Alkyl fluoride / Alkyl halide / Amine / Aminopyridine / Aminopyrimidine / Aromatic heteromonocyclic compound / Azacycle / Dialkyl ether / Dialkylarylamine / Ether
show 16 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organofluorine compound, aminopyrimidine, ring assembly, morpholines, aminopyridine (CHEBI:71954)

Chemical Identifiers

UNII
0ZM2Z182GD
CAS number
944396-07-0
InChI Key
CWHUFRVAEUJCEF-UHFFFAOYSA-N
InChI
InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)
IUPAC Name
5-[2,6-bis(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluoromethyl)pyridin-2-amine
SMILES
NC1=CC(=C(C=N1)C1=NC(=NC(=C1)N1CCOCC1)N1CCOCC1)C(F)(F)F

References

General References
Not Available
PubChem Compound
16654980
PubChem Substance
347828035
ChemSpider
17588300
BindingDB
50380363
ChEBI
71954
ChEMBL
CHEMBL2017974
ZINC
ZINC000043154039
PDBe Ligand
SD5
Wikipedia
Phosphoinositide_3-kinase_inhibitor
PDB Entries
3sd5 / 5m7e

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentBreast Cancer1
3Not Yet RecruitingTreatmentHead and Neck Carcinoma1
3TerminatedTreatmentMetastatic Breast Cancer / Metastatic Breast Cancer HR+, HER2-1
2Active Not RecruitingTreatmentAdvanced thymic carcinoma1
2Active Not RecruitingTreatmentMelanoma1
2Active Not RecruitingTreatmentMetastatic (Spread to Other Areas of the Body) / Prostate Cancer1
2Active Not RecruitingTreatmentThyroid Cancers1
2CompletedTreatmentAdvanced Endometrial Cancer1
2CompletedTreatmentBreast Cancer4
2CompletedTreatmentBreast Cancer / Metastatic Breast Cancer / Triple Negative Breast Cancer (TNBC) / Tumors Metastatic to Brain1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.81 mg/mLALOGPS
logP2.44ALOGPS
logP2.56ChemAxon
logS-2.7ALOGPS
pKa (Strongest Basic)5.94ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area89.63 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity103.58 m3·mol-1ChemAxon
Polarizability39.25 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 14:38 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates